For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221130:nRSd0014Ia&default-theme=true
RNS Number : 0014I Benchmark Holdings PLC 30 November 2022
30 November 2022
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Full Year Results for the Financial Year ended 30 September 2022
A year of sustained growth and strategic delivery
Benchmark, the aquaculture biotechnology company, announces its full year
audited results for the year ended 30 September 2022 (the "period").
Financial highlights - strong FY2022 results delivered ahead of original
market expectations
· Revenue increase of 27% (+21% CER)
o Advanced Nutrition - excellent performance as the Company continued to
capitalise on renewed commercial focus and recovery in the shrimp markets post
pandemic; revenues increased by 14% (+7% CER)
o Genetics - strong performance benefitting from high demand for the
Company's salmon eggs delivered from Benchmark's new incubation centre in
Iceland; revenue growth +24% (+21% CER)
o Health - first full year of sales from new sea lice solution Ectosan® Vet
and CleanTreat® resulting in revenue growth of 157% (+157% CER)
· Adjusted EBITDA +60% (+54% CER) driven by growth in the three
business areas and continued financial discipline
· Adjusted EBITDA margin of 20% (FY21: 16%). Adjusted EBITDA margin
excluding fair value uplift from biological assets increased to 19% (FY21:
13%)
· Loss for the period increased to £30.5m as a result of increased
depreciation associated with CleanTreat® units and higher net finance
expenses
· Disciplined investment in growth areas with tangible capex totalling
£10.8m
· Refinancing of NOK 850m bond and post period end refinancing of USD
$15m RCF
· Cash and cash equivalents of £36.4m and available liquidity of
£45.8m
· At 28 November, cash and cash equivalents of £35m and available
liquidity of £51m
£m FY 2022 FY 2021 % AER % CER**
Revenue 158.3 125.1 27% 21%
Adjusted
Adjusted EBITDA(1) 31.2 19.4 60% 54%
Adjusted EBITDA excluding fair value uplift from biological assets 29.6 16.1 83% 76%
Adjusted operating profit 9.1 10.8 (15%) (23%)
Statutory
Operating loss (7.9) (5.4) (46%) (61%)
Loss before tax (23.2) (9.2) (152%) (167%)
Loss for the period (30.5) (11.6) (163%) (168%)
Basic loss per share (p) (4.60) (1.93) (138%)
Net debt(3) (73.7) (80.9) 9%
Net debt excluding lease liabilities (47.5) (56.9) 17%
** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Business Area Performance - £m FY 2022 FY 2021 % AER % CER**
Revenue
Genetics 58.0 46.8 24% 21%
Advanced Nutrition 80.3 70.5 14% 7%
Animal Health 20.1 7.8 157% 157%
Adjusted EBITDA(1)
Genetics 16.0 11.5 39% 39%
- Net of fair value movements in biological assets 14.4 8.2 75% 76%
Advanced Nutrition 19.0 13.8 38% 29%
Animal Health 0.1 (2.7) 104% 102%
** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.
Operational highlights
Advanced Nutrition - excellent performance
· Excellent performance driven by commercial focus, continued innovation
and cost discipline, supported by positive market conditions
· New products and product upgrades brought to market including Artemia
separation tool 'Sep-Art Automag' which delivers sustainability benefits
· Closure of trial facilities in Thailand as part of strategy to
optimise operations
Genetics - continued growth
· Continued growth in core salmon egg business with record sales in
FY2022
· New incubation centre in Iceland delivering increased quality and
capacity which was instrumental in satisfying peak demand in the year
· Commercialisation of SPR shrimp progressing, leveraging Advanced
Nutrition's market position in shrimp
Health - further commercialisation progress
· Roll-out of Ectosan® Vet and CleanTreat® progressing with increasing
customer adoption. Solution delivered consistent efficacy above 99%, with
enhanced animal welfare and protection of the environment
· Marketing Authorisation for Ectosan® Vet and CleanTreat® in Norway
extended to one reuse of water
· Marketing Authorisation obtained in the Faroe Islands
· Ectosan® Vet patent grant approved giving 20 year protection
Group - ESG commitment, continued integration and delivery against strategic
priorities
· ESG - on track to achieve our Net Zero targets with implementation of
carbon reduction plan; issue of first Green bond validates strong ESG
credentials
· Continued Group integration by combining the commercial efforts across
our salmon products, making the business more customer-centric and increasing
efficiency
· Excellent employee engagement results aligned to the Group's goal of
making Benchmark "A Great Place to Work"
· Looking forward we remain focused on our four strategic pillars:
o Maintain and grow our leadership position in established markets
o Expand our business through the launch of new products and entry into new
markets
o Continue to embed the new One Benchmark culture and to integrate the Group
to realise synergies
o Pursue add-on acquisitions within core areas, adhering to strict criteria
and making optimal use of our capital structure
Current trading and outlook - good momentum and tracking in-line with
management expectations
· Good start to the year and positive momentum in the business
· The diversified nature of the business and management's proactive
commercial approach creates resilience and mitigates the potential impact from
ongoing cost inflation and macroeconomic pressures
· Management expects that the recently announced change in tax regime for
aquaculture producers in Norway will have a marginal direct effect on the
Group's business
· Well progressed towards dual listing on Euronext Growth Oslo as announced
this morning; intention to uplist to the Oslo Børs in H1 calendar year 2023
· Longer term, management believe the Group is uniquely positioned in an
industry that is structurally growing driven by megatrends
Trond Williksen, CEO, commented:
"In FY2022 Benchmark delivered another year of growth and strategic progress,
underpinned by four quarters of consistently improved financial results. This
demonstrates the success of our restructuring and culture change, the quality
and potential of our business and the talent and commitment of our people, as
well as the underlying strength of our markets.
"Our strategic and commercial focus have contributed to strong results. Going
into the new financial year, there is good momentum in line with our
expectations and positive dynamics in our industry creating significant
opportunities to deliver value for all our stakeholders."
Details of analyst / investor call today
There will be a call at 9.00am UK time today for analysts and investors. To
attend the call, please register via Investor Meet Company:
https://www.investormeetcompany.com/benchmark-holdings-plc-analyst-meeting-q4-results/register-investor
(https://www.investormeetcompany.com/benchmark-holdings-plc-analyst-meeting-q4-results/register-investor)
.
You can address registration questions to MHP Communications on +44 (0)20 3128
8004, or by email on benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com) .
Enquiries
Benchmark Holdings plc Tel: 0114 240 9939
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black, Freddie Barnfield, Duncan Monteith
MHP Tel: 020 3128 8004
Katie Hunt, Reg Hoare, Veronica Farah benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark's mission is to enable aquaculture producers to improve their
sustainability and profitability. We bring together biology and technology, to
develop innovative products which improve yield, quality and animal health and
welfare for our customers. We do this by improving the genetic make-up, health
and nutrition of their stock - from broodstock and hatchery through to nursery
and grow out. Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics and sea lice
treatments. Find out more at www.benchmarkplc.com
(http://www.benchmarkplc.com)
Chairman's Statement
A year of delivery
I am proud to report a second year of strong performance for Benchmark,
continuing a path that started in 2019 with a substantial reorganisation of
the business and the appointment of a new management team.
In 2022 our focus was on delivering profitable growth in each of our
established core areas, on fully commercialising our recently launched
products, and on maintaining disciplined cash management and investment.
Together, this translated into a very strong performance with significant top
line growth and improved underlying profitability. We remain committed to
continuing on this path of consistent delivery to reach sustainable
profitability and cash generation, and ultimately attractive shareholder
returns.
Macroeconomic and geopolitical conditions in the year materially affected
markets around the world and impacted the performance of our shares. Smaller
growth companies were particularly affected by fund outflows and a change in
investor sentiment. This is particularly disappointing given the significant
progress that the Company made during the year. However, I am confident that
we are building fundamental value for our shareholders, which will crystallise
in the coming years.
Performance
The Group delivered excellent growth in the year with a 27% increase in
revenue and an 83% increase in Adjusted EBITDA excluding fair value movements
from biological assets. Importantly, each of our three business areas
delivered higher revenues and Adjusted EBITDA, with growth in established
areas and progress in the commercialisation of new solutions, including
Ectosan® Vet and CleanTreat® and SPR shrimp genetics. We now have a solid,
diversified, well-balanced Group across geographies and species which provides
multiple opportunities for growth as well as resilience to volatility in
specific markets.
Adjusted EBITDA is the key profitability measure we use to track underlying
performance. In FY22 the Group delivered Adjusted EBITDA of £31.2m (FY21:
£19.4m) and an Adjusted EBITDA margin of 20% (FY21: 16%) as a result of top
line growth, increased asset utilisation and good cost control.
There was an increase in depreciation related to our CleanTreat® operations
and higher net finance costs reflecting foreign exchange volatility as well as
costs associated with the refinancing of our pre-existing NOK bond. This led
to a net loss for the year of £30.5m (FY21: £11.6m loss).
Financing
An area of focus for the Board in FY22 was to maintain a solid financial
position to support the Company's trading momentum and growth strategy. To
this end, in November 2021 the Company raised £20.7m through a placing of
shares with existing and new shareholders which provided additional headroom.
Later in the year, in September 2022, in challenging macroeconomic and market
conditions, the Company successfully refinanced its NOK 850 million bond which
was due to mature in June 2023. The refinancing was achieved through the issue
of a NOK 750 million unsecured green bond maturing in 2025 which validates our
strong ESG credentials, and places us in a solid financial position,
particularly in light of the ongoing challenging environment in the financial
markets.
Sustainability
Benchmark's mission is to drive sustainability in aquaculture. In alignment
with our mission, sustainability is front and centre in our strategy and our
operations. Our products are designed to deliver improved yield and animal
welfare, improving resource efficiency and reducing environmental impact. In
addition, we manage our own operations responsibly with an ambitious
commitment to energy transition. In 2022, we made substantial progress towards
our Net Zero goals by developing a comprehensive emissions reduction programme
for our Thailand facility centred around the installation of solar panels
which commenced in 2022. In addition, during the year we conducted a climate
risk assessment across the Group for the first time representing an important
step towards TCFD (Task Force on Climate-related Financial Disclosures)
compliance in 2023.
Board
On 29 November 2021, the Board appointed Atle Eide as Non-Executive Director.
Given Atle's previous role as a director of Kverva AS, a significant
shareholder in the Company, he is not deemed an independent director. Atle has
extensive experience in the seafood industry including in his former roles as
Chairman of Salmar ASA and CEO of Mowi ASA, and as an investor, bringing value
to the Board.
Regular Board evaluation is an important element in maintaining high standards
of corporate governance and Board effectiveness. In 2022, the Board conducted
an internal evaluation exercise. The results, which were reviewed at the
September 2022 Board meeting, confirmed that the Board continues to perform
effectively and with a high degree of Director engagement.
Board meetings were held at various Group locations during the year, enabling
the Directors to interact broadly with our people, promoting engagement and an
understanding of local cultures.
Euronext Growth Listing
During the year, we communicated our intention to pursue a listing in Oslo as
the world's largest seafood-focused market. Our decision followed extensive
consultation with shareholders, concluding that the Company would benefit from
a listing in Oslo to expand its access to a global base of specialist seafood
investors and analysts and to improve liquidity in our shares.
The Company's plan to launch a dual-listing on Euronext Growth Oslo before the
end of the calendar year is well progressed. The dual-listing represents a
first step towards a listing on the Oslo Stock Exchange (Oslo Børs), the
world's leading listed venue for seafood and aquaculture companies. The
Board intends to uplist the Company to the Oslo Børs from Euronext Growth
Oslo in the first half of the calendar year 2023. In tandem, we intend to
consult with shareholders on whether to maintain the admission of the
Company's shares to trading on AIM. The intended dual listing on Euronext
Growth Oslo and the uplisting to the Oslo Børs are both subject to market
conditions.
In connection with its proposed admission to Euronext Growth Oslo, Benchmark
has today announced the terms of a potential private placement and retail
offering in Norway, representing in aggregate 5% of the Company's enlarged
issued share capital.
Looking ahead
While macroeconomic conditions remain challenging as we enter 2023 with high
levels of cost inflation and interest rates affecting consumer spend,
Benchmark has started the year positively and is prepared to meet the
challenges of an inflationary environment through a combination of price
increases and operational efficiencies to mitigate inflationary pressure.
Moreover, the Company enters 2023 with good momentum, and with a clear
strategy that will help deliver continued growth and progress towards
sustainable profitability and cash generation.
Longer term, Benchmark is well placed to deliver growth and attractive
shareholder returns. The Company is well invested, with multiple, visible
growth opportunities underpinned by existing infrastructure. This, together
with Benchmark's leading market positions and the megatrends driving the
aquaculture industry, give us confidence in the future.
Our strong performance this year could not have been achieved without the
efforts of the 800+ people who make up this great company. Their hard work,
integrity and expertise have shone through, and on behalf of the Board, I want
to thank them for everything they have done, and continue to do, for
Benchmark. I also want to thank and acknowledge our shareholders and other
stakeholders for their continued support.
Peter George
Chairman
Chief Executive Officer's Review
Sustained growth and strategic delivery
Benchmark delivered excellent growth in revenue and Adjusted EBITDA in FY22,
building on its track record of continuous quarterly improvement since the
restructuring was completed in FY20. Revenues grew by 27% to £158.3m in the
year, and Adjusted EBITDA excluding fair value movements from biological
assets grew by 83% to £29.6m. On a constant exchange rate basis, Group
revenue and Adjusted EBITDA excluding fair value movements, were up 21% and
76%, respectively. Since the end of FY20, we have increased revenues by 50%
and Adjusted EBITDA by 115%.
Despite the strong revenue growth and the progress in our underlying
profitability, the Group reported a loss before tax of £23.2m, (2021: loss of
£9.2m). This is due to a £11.5m increase in depreciation principally
related to the leased vessels used in the CleanTreat® operations and an
increase in finance costs due to higher interest rate charges and non-cash
movements associated with the accounting for the refinancing of our
pre-existing NOK bond. Total loss for the year was £30.5m (FY21: £11.6m).
Trading and operational performance was strong in our three business areas and
all reported a significant increase in revenues and Adjusted EBITDA. Advanced
Nutrition continued its growth trend with revenues up by 14%; Genetics
increased revenues by 24%, benefitting from strong demand for our salmon eggs,
which we were able to fulfil through our recent investment in a new bio-secure
incubation centre in Iceland; and Health reported 157% growth in revenues,
benefitting from the launch of its sea lice solution, Ectosan® Vet and
CleanTreat®. While the commercialisation of Ectosan® Vet and CleanTreat® is
still in the initial phase, we now have three well-performing and growing
business areas with a visible path to Group profitability and cash generation.
We maintained our ongoing financial discipline on costs, investment and cash.
Operating costs and R&D were £51.4m, a 14% increase from the prior year
due to higher activity levels and cost inflation. Our ongoing cost control,
together with higher asset utilisation resulted in an Adjusted EBITDA margin
(excluding fair value movement from biological assets) of 19% (FY21: 13%).
Capex during the year totalled £10.8m (FY21: £18.0m) reflecting our new
investment discipline and completion of investments to support our main growth
vectors. Our main investment was the construction of a new incubation centre
for salmon eggs in Iceland which allows us to meet seasonal periods of peak
demand. This was particularly welcome this year when our customers experienced
a shortage of supply in our market.
By business area, Genetics reported revenues of £58m, 24% above last year
driven primarily by higher salmon egg sales. Adjusted EBITDA before fair value
movement in biological assets of £14.4m was 75% above last year (FY21:
£8.2m). Strategically, we continued to build on our stronghold in salmon,
covering all production paradigms and producing regions. In addition, our
focus was on the launch of our SPR shrimp genetics in Asia and the Americas,
an important growth vector for the Group in the coming years. Innovation is a
key driver of our success in Genetics and during the year we strengthened our
team with the appointment of Dr. Ross Houston as Director of Innovation for
our Genetics business and Chair of our Group Innovation Board.
Advanced Nutrition reported revenues of £80.3m, 14% ahead of FY21 driven by
increased sales in all product areas - Artemia, Health and Diets. Adjusted
EBITDA of £19.0m was 38% up on the prior year (FY21: £13.8m). We continued
to capitalise on our enhanced commercial focus and structure and on our
efforts to improve our operations to drive efficiency and margins. This
included the closure of our trial facility in Thailand moving to more
effective solutions in partnership with external providers.
In Health we reported revenues of £20.1m, (FY21: £7.8m) as a result of
increased Ectosan® Vet and CleanTreat® sales following the commercial launch
at the end of last year. Adjusted EBITDA was £0.1m (FY21: loss £2.7m). The
roll-out of Ectosan® Vet and CleanTreat® is one of the Group's key strategic
priorities and we made further progress during the year, increasing adoption
of the new solution in the market. In addition, we reached important
milestones towards optimising our solution. Treatment times were reduced, a
marketing extension for a second re-use of treatment water was obtained and we
continue to work with our customers on new configurations for our CleanTreat®
systems adapted to our customer's infrastructure.
Strategic delivery
Benchmark's strategy is directed at becoming the leading aquaculture
biotechnology company driving sustainability and delivering attractive
shareholder returns. Our strategy represents a roadmap to achieve this and has
three main elements:
· maximising the opportunity in our established business through a
proactive commercial effort and continuous operational improvement,
benefitting from structural growth in the industry
· extending our platform through additions to our product offering and
geographic expansion within our core areas
· pursuing add-on opportunities within our core areas and applying
disciplined return parameters
At the beginning of 2022, we set out five strategic Group priorities in areas
that will drive growth and profitability for the Group. These were the
roll-out of Ectosan® Vet and CleanTreat®, the commercialisation of our
shrimp genetics, regaining leadership in Artemia within our Advanced Nutrition
business and delivering ESG and People agendas that are aligned to our mission
and that support our new performance-driven culture. This clear strategic
focus enables us to direct resources and monitor progress. Overall, progress
in all areas was positive in 2022.
As mentioned above we made important strategic progress in the roll-out of our
Ectosan® Vet and CleanTreat® solution.
Our SPR shrimp in Genetics was commercially launched in the year with growing
sales albeit from a small initial base. Our leading position in the shrimp
market through our Advanced Nutrition business creates an important synergy
facilitating market entry.
In Advanced Nutrition, our priority for FY22 was to regain a leadership
position in the global Artemia market following a period of oversupply which
resulted in lower prices in the market affecting our premium positioning.
Through a renewed commercial effort brought about by a management change in
the business, we have successfully recovered our position and gained momentum
for the future.
Looking forward to 2023, our Group priorities represent a continuation of our
current effort including the roll-out of Ectosan® Vet and CleanTreat® and
maintaining our leadership position in Advanced Nutrition across our three
product areas. In Genetics, our focus will be on becoming the supplier of
choice for salmon eggs across all markets while continuing our work to
commercialise our shrimp genetics.
'One Benchmark' culture
One of our key focus areas over the last two years has been to create a
stronger, more aligned group to drive commercial performance and realise
synergies and efficiencies. The primary engine of this culture change is a
strategic priority framework working alongside a performance management
framework with our values to guide our behaviour.
This unified culture has allowed us to drive further integration by combining
functions and establishing cross-group initiatives which are delivering
results. An example of this is the combination of the marketing and commercial
functions around species allowing us to become more customer-centric.
Looking forward
We have had a good start to the year and there is good momentum in the
business. Cost inflation and other macroeconomic pressures will continue to be
a feature across the world in 2023 and we are not immune. However, we have a
well diversified, balanced business which creates resilience to challenges in
individual markets as well as opportunities. In addition, we will continue to
proactively mitigate potential pressure on our business and our margins
through pricing, supplier management and operational improvements. The
recently announced change in the tax regime for aquaculture producers in
Norway is expected to have a marginal direct effect on our business.
Looking further into the future, Benchmark is uniquely positioned in an
industry that is structurally growing and driven by multiple megatrends. This
creates significant opportunity for growth and increasing returns for
shareholders in the near and medium term and for many years to come.
Trond Williksen
Chief Executive Officer
Financial Review
Strong and positive performance in the year
FY22 has been a year where our focus on commercial execution has paid off.
With all three business areas now commercially focused, we have delivered
growth across the board and have been able to consistently deliver progress on
our strategic objectives. We have been able to leverage off the investments
made in FY21 to meet demand in the market within our Genetics business area.
We have continued to generate sales growth above market growth , albeit aided
by forex tailwinds from a strong US dollar in Advanced Nutrition, and have had
a full year of Ectosan®Vet and CleanTreat® sales moving Health from being a
development business area to a commercial one.
Overview of reported financial results
During 2022, the Group's focus was on continuing to deliver a strong
commercial result and advancing its strategic priorities.
Advanced Nutrition continued a track record of strong commercial focus in
2022. Genetics also experienced strong sales in the year and with a full year
of Ectosan® Vet and CleanTreat® sales in Health this resulted in an increase
in Group revenue of 27% to £158.3m in the year (2021: £125.1m). This
increase in sales meant that Gross Profit increased to £83.1m (2021:
£65.6m). Gross Margin was flat at 52% (2021: 52%). Using the same foreign
exchange rates experienced in 2021 (constant currency(5)) revenue increased by
21%.
As Reported (£m unless otherwise stated) 2022 2021 % AER % CER**
Revenue 158.3 125.1 27% 21%
Operating loss (7.9) (5.4) (46%) (61%)
Loss before tax (23.2) (9.2) (152%) (167%)
Loss for the period (30.5) (11.6) (163%) (168%)
Basic loss per share (p) (4.60) (1.93) (138%) -
** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
Adjusted Measures (£m unless otherwise stated) 2022 2021 % AER % CER**
Gross profit 83.1 65.6 27% 22%
Gross profit % 52% 52% - -
Adjusted EBITDA(1) 31.2 19.4 60% 54%
Adjusted EBITDA(1) margin % 20% 16% - -
Adjusted Operating Profit(2) 9.1 10.8 (15%) (23%)
Net debt(3) (73.7) (80.9) 9% -
** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Business area performance
We continued to manage costs across the Group very closely. Operating costs
increased by 17% to £44.7m (2021: £38.2m) due to the investment in new
growth areas, mainly the ramp-up of activities for the launch of Ectosan®Vet
and CleanTreat® and increased activity post the pandemic. Expensed R&D
decreased by 5% to £6.7m (2021: £7.0m).
Adjusted EBITDA increased by 60% to £31.2m (2021: £19.4m) driven by
increased sales in Advanced Nutrition, a strong finish to the year in Genetics
and a full year of commercial activities in Health for Ectosan®Vet and
CleanTreat® as well as ongoing cost control.
Adjusted measures
We continue to use adjusted results as our primary measures of financial
performance. We believe that these adjusted measures enable a better
evaluation of our underlying performance. This is how the Board monitors the
progress of the Group.
We use growth at constant exchange rate metrics when considering our
performance, whereby currency balances are retranslated at the same exchange
rate in use for the prior year to illustrate growth on a currency like for
like basis.
In line with many of our peers in the sector, we highlight expensed R&D on
the face of the income statement separate from operating expenses.
Furthermore, we report earnings before interest, tax, depreciation and
amortisation ("EBITDA") and EBITDA before including exceptional and
acquisition- related items ("Adjusted EBITDA"). The activities of the Group's
equity accounted investees are closely aligned with the Group's principal
activities, as these arrangements were set up to exploit opportunities from
the Intellectual Property ("IP") held within the Group. As a result, to ensure
that adjusted performance measures are more meaningful, the Group's share of
the results of these entities is included within Adjusted EBITDA. We also
report this adjusted measure after depreciation and amortisation of
capitalised development costs ("Adjusted Operating Profit") as the Board
considers this reflects the result after taking account of the utilisation of
the recently expanded production capacity. In addition, in line with the
Salmon industry, we also report AEBITDA excluding fair value uplift under IAS
41. Available liquidity, being cash and undrawn facilities, is an important
metric for management of the business as it gives a measure of the available
liquid funds and is also a key financial covenant in the Group's main debt
facilities.
Genetics
Genetics delivered good growth in revenue driven by sales of salmon eggs where
volumes increased by 20% to 291 million eggs. Revenues of £58.0m were up 24%
(2021: £46.8m), +21% in constant currency.
Demand for eggs in Norway increased by 23% during the year, which we were able
to supply due to the increased capacity in our new incubation house in
Iceland. We also saw increased demand from all other territories in the year.
This resulted an increase in revenue from salmon eggs of 24% to £38.3m (2021:
£30.9m).
In non-product based revenue streams, Genetics Services continued to deliver
in the year reflecting the strength and depth of expertise of our Genetics
team and our IP in the business, contributing £1.3m (2021: £1.3m). Revenues
from harvested fish were aided by increased salmon prices producing harvest
income in the year of £8.5m (2021: £6.2m). Royalties earned from use of our
genetic IP fell in the year, with sales down to £0.8m (2021: £1.0m) as the
expected unwind of contracts continues for the next year. Revenues from other
products totalled £9.1m (2021: £7.4m).
Gross profit increased by 24% in 2022 to £32.0m (2021: £25.9m) and gross
margin remained unchanged at 55%. Increased gross profit from the core
salmon business was offset by losses in the newly launched SPR shrimp and
tilapia, and the non-cash fair value increase in biological assets fell by 52%
in 2022 to £1.6m (2021: £3.3m).
Shrimp and tilapia, both of which are areas of investment, delivered combined
Adjusted EBITDA losses in the period of £3.1m (2021: £1.4m). The shrimp loss
of £1.7m (2021: £0.9m) followed the ceasing of capitalising costs after the
commercial launch of SPR shrimp in the year. We capitalised costs of £1.0m in
2022 related to development of the shrimp nucleus before it launched
commercially. The loss in Tilapia was driven by the capacity expansion being
delayed due to COVID and a one-off £0.4m loss related to a provision for
committed running costs, over and above the lease obligations, on a production
site which is no longer used.
R&D spend was lower and operating costs were higher than 2021 by £0.6m
and £2.2m respectively as the business grew. R&D reduced due to good cost
optimisation in this area. R&D activities in this business area are
focused on developing the traits of growth, disease resistance and sea lice
resistance by selecting the best performing animals from each generation
supported by cutting edge genetic technologies. The search for markers for new
traits that can be included in the breeding programme continues.
The share of profits/losses from the equity accounted investees relates
primarily to the joint venture with Salmar Genetics AS which delivered a share
of loss of £0.5m (2021: loss of £0.6m). In both 2022 and 2021, the joint
venture suffered a biological event which drove the losses.
Genetics has continued to establish its facility in Chile and with overall
AEBITDA losses of £3.4m and £0.6m invested in capex in this new facility in
2022 (2021: £2.6m and 1.3m). The facility has potential production capacity
of 50 million eggs and is currently utilising capacity of around 30 million
eggs. During the year we sold 4 million eggs.
All these factors contributed to increased AEBITDA of £16.0m (2021: £11.5m)
and AEBITDA margin of 28% (2021: 25%). AEBITDA excluding fair value increased
by 75% to £14.4m, an AEBITDA margin of 25% (2021: 17%).
Advanced Nutrition
Throughout 2022, Advanced Nutrition delivered a strong performance driven by
continued commercial focus. As a result, revenues in Advanced Nutrition
increased by 14% in the year (7% at CER). This is notable as some key markets
continued to be impacted by COVID-19 and the business faced significant
logistical challenges as a result of the pandemic. The strong commercial focus
has allowed us to continue to strengthen our position and take increased
market share.
In 2022, 73% of our revenues derived from shrimp with the balance 27% of
derived from the Mediterranean sea bass and sea bream sector.
By product area, we drove growth in all product areas. Artemia grew revenues
by 7% (at CER) to £37.1m, followed by diets up 7% (at CER) to £35.1m. Health
which covers our probiotic and environmental pond management portfolio grew
revenues by 6% (at CER) to £8.1m.
The increase in sales of £9.8m resulted in an increase in gross profit of
£6.6m and drove the gross margin up from 51% to 53%. This increase in margin
was offset in part by an increase in operating costs as we grew the business,
but there continued to be good cost control throughout this year. This led to
Advanced Nutrition reporting AEBITDA of £19.0m (2021: £13.8m) and an
increase in AEBITDA margin from 20% to 24%.
Within this business area, an important barrier to entry is the access to GSL
Artemia where we, through our relationship with the Great Salt Lakes
Cooperative have access to 44% of the annual harvest of Artemia from the Great
Salt Lakes. Whilst the harvest can vary from year to year and we saw very high
harvest levels in 19/20, the last two harvests were lower; the 20/21 harvest
was 1,168 metric tonnes and the 21/22 harvest was 1,104 metric tonnes which
are considered normal harvest levels.
Health
Health reported revenue of £20.1m (2021: £7.8m) reflecting the first full
year of sales of Ectosan®Vet and CleanTreat® of £14.8m of which £2.5m
relates to revenue for vessel-related costs and a marginal increase in sales
of our existing sea lice treatment, Salmosan® Vet of £5.4m (2021: £5.1m).
Gross profit increased by £4.9m to £8.6m, a margin of 43%, with the launch
of Ectosan®Vet and CleanTreat® combined with increased margins from
Salmosan® Vet.
During the year, the focus of this business area was to launch Ectosan®Vet
and CleanTreat® in Norway. The first vessel launched in August 2021, with the
second vessel launching in December 2021. These activities drove an increase
in operating costs to £8.1m (2021: £6.2m) Adjusted EBITDA for the business
area was £0.1m (2021: £2.7m).
Cost Inflation
As noted earlier, cost control remains of significant importance in Benchmark
and in the current cost environment becomes even more so. During the year, we
focussed on a number of areas to mitigate cost inflation. In Nutrition, the
Operations team focused on ensuring lean production and with better volumes,
getting better cost per units through to support margin. The procurement team
were consistently challenged to maintain or get better pricing for raw
materials. From an energy perspective, we have access to lower cost energy in
both Norway and Iceland where we have Genetics production facilities and we
have also commenced the plan to put solar panels on our facility in Thailand.
Whilst we are not immune from inflation, we as a business seek to use multiple
ways to mitigate this as we move forward.
Exceptional items
Items that are material because of their nature whose significance is
sufficient to warrant separate disclosure and identification within the
consolidated financial statements are referred to as exceptional items. The
separate reporting of exceptional items helps to provide an understanding of
the Group's underlying performance.
Exceptional expenses were fully offset by exceptional credits in the year.
Exceptional expenses related to legal and professional costs in relation to
the proposed dual listing on the Oslo exchange of £0.8m, and restructuring
costs of £0.4m including those relating to a legal dispute within a divested
business, and costs relating to the closure of the Thai research centre in
Advanced Nutrition. These costs were offset by a credit of £1.2m relating to
additional contingent consideration received in the period following the
disposal of Aquaculture UK on 7 February 2020 and Improve International on 23
June 2020.
Depreciation, amortisation and impairments
Depreciation and impairment of tangible assets was £19.9m (2021: £8.4m),
with depreciation charge of £19.9m (2021: £8.5m) and impairment reversal of
£nil (2021: £0.1m). The depreciation charge in the year increased due to the
launch of CleanTreat® where the vessels are right-of-use assets held under
lease agreements. In total, depreciation and impairment charges on leased
assets under IFRS 16 was £11.3m (2021: £3.3m).
Amortisation and impairments of intangible assets totalled £19.2m (2021:
£16.3m). The amortisation charge includes £2.2m (2021: £0.3m) relating to
capitalised development following commercialisation of Ectosan®Vet and
CleanTreat® and SPR shrimp.
Research and development
£m Expenses Total expensed and capitalised
2022 As % of 2021 As % of 2022 As % of 2021 As % of sales
sales
sales sales
Expensed R&D by business area
Genetics 4.3 7% 4.9 10% 5.3 9% 6.8 15%
Advanced Nutrition 2.0 2% 1.9 3% 2.1 3% 2.2 3%
Health 0.4 2% 0.2 3% 1.0 5% 2.9 36%
Total research and development 6.7 4% 7.0 6% 8.4 5% 11.8 9%
Expensed R&D activities decreased in the year by £0.3m with Genetics
having good cost optimisation in this area while continuing to focus on
improvements in the breeding nucleus. Health spending remained low due to
their significantly reduced R&D programmes. Genetics' research is focused
around continually developing new disease and parasitic resistant traits as
well as growth traits which we can breed into our products. Advanced
Nutrition's focus is on expanding our product portfolio and driving growth
through product improvements.
Other operating costs
£m 2022 As % of 2021 As % of
sales sales
Operating Expenses by Business Area
Genetics 11.1 19% 8.9 19%
Advanced Nutrition 21.5 27% 19.9 28%
Health 8.1 41% 6.2 79%
Corporate (net) 4.0 3.2
Total operating expenses 44.7 28% 38.2 31%
Other operating costs increased from £38.2m in 2021 to £44.7m in 2022. The
increase in costs include increased costs in Health as we had a full year of
commercial launch of Ectosan®Vet and CleanTreat® and higher costs as we
commercially launched Chile and SPR shrimp and continued to grow in Nutrition.
Net finance costs
£m Analysis
2022 2021
Net Finance expenses
Interest Income (0.3) (0.1)
Foreign Exchange losses/(gains) (2.8) (2.8)
Interest on bond and bank debt 6.2 6.0
Amortisation of deferred financing fees 1.9 1.0
Penalty for early settlement of the bond 1.6 -
Movements of cash flow hedges 7.0 (1.4)
Finance lease interest 1.7 1.1
Total net finance expenses 15.3 3.8
The Group incurred net finance costs of £15.3m during the year (2021:
£3.8m). Included within this was interest charged on the Group's
interest-bearing debt facilities of £9.7m (2021: £6.9m) of which £1.6m
related to the early redemption penalty for the settlement of the NOK bond and
with a further £1.9m of this being amortisation of the deferred finance costs
(2021: £1.0m). Net foreign exchange gains of £2.8m (2021: net gain of
£2.8m) arose due to the movement in exchange rates on intercompany loans and
external debt. Movements on the cash flow hedges associated with the Groups
NOK bond debt resulted in charges of £7.0m (2021: gain of £1.4m).
Statutory loss before tax
The loss before tax for the year at £23.2m is higher than the prior year
(2021: loss of £9.2m). This was a result of the positive trading result
offset by the increased depreciation on right-of-use assets and amortisation
of intangibles following the launch of Ectosan® Vet/CleanTreat® and SPR
shrimp, as well as higher net finance costs as discussed above.
Taxation
There was a tax charge on the loss for the year of £7.3m (2021: £2.4m),
mainly due to overseas tax charges in Genetics and Advanced Nutrition in
territories where no loss relief is available, partially offset by deferred
tax credits on intangible assets mainly arising on consolidation from
acquisitions.
Other Comprehensive Income
In addition to the loss for the year of £30.5m, a significant item to be
reclassified to the income statement related to foreign exchange
translation differences. The gain on this account was £47.2m. This gain
was driven by a strong USD impacting two main items, firstly the retranslation
of the foreign currency denominated subsidiary balance sheets in GBP at the
year end of £36.3m and the foreign exchange of £10.9m associated with items
which are designated as net investment hedges or internal loans which are
deemed to be equity and as such the exchange associated with these goes
directly to other comprehensive Income.
Reported loss for the year
The loss for the year was £30.5m (2021: loss of £11.6m).
Earnings per share
Basic loss and diluted loss per share were both 4.60p (2021: loss per share
1.93p). The movement year on year is due to the movement in the result as well
as the increase in the weighted average number of shares in issue of 28m.
Dividends
No dividends have been paid or proposed in either 2022 or 2021 and the Board
is not recommending a final dividend in respect of the year ended 30 September
2022.
Biological assets
A feature of the Group's net assets is its investment in biological assets,
which under IAS 41 are stated at fair value. At 30 September 2022, the
carrying value of biological assets was £46.7m (2021: £38.4m). This increase
is due principally to the increase in the biomass of broodstock as we continue
to expand production at Salten and Chile and increased eggs available for sale
in FY23. The fair value uplift on biological assets included in cost of goods
for the year was £1.6m (2021: £3.3m).
Intangibles
Additions to intangibles were £1.9m (2021: £5.0m) with the main area of
investment being capitalised development costs which in the year decreased by
£3.1m to £1.7m (2021: £4.8m). R&D costs related to products that are
close to commercial launch have to be capitalised when they meet the
requirements set out under IAS 38. In this financial year, the main
development projects capitalised were as follows:
· Ectosan®Vet/CleanTreat® (£0.6m)
· SPR shrimp (£1.0m)
· Patents for genetics (£0.2m)
· Live food alternative diets (£0.1m)
Capital expenditure
During 2021, we invested in a number of growth initiatives and in 2022 there
remained some spend to complete them. The Group incurred tangible fixed asset
additions of £10.8m (2021: £18.0m) broken down as follows:
· Health: £2.6m
· Genetics: £5.6m
· Nutrition: £2.6m
Within Health, there was an investment in a third CleanTreat® unit and
finalising the mobilisation of the second vessel on which the second
CleanTreat® units are situated. During the year, this third CleanTreat® unit
was reclassified to inventory as it is intended to be used in the new business
model whereby the units are sold to customers rather than owned by us. Capex
associated with our Genetics business was £5.6m where we finished the new
incubation house for our Icelandic facility (£2.3m) and commenced building
new tanks at Salten to support ramping up to the 150 million egg capacity at
that facility which will continue in FY23 (£1.2m) and we continue to invest
in our other growth initiatives SPR Shrimp and Tilapia in the US. In Nutrition
we continued to invest in the two manufacturing facilities to support
continued growth.
Cash flow, liquidity and net debt
Movement in net debt £m
Net debt at 30 September 2021 (80.9)
Cash generated from operations excluding working capital and taxes paid 30.3
Movement in working capital (12.0)
Capital expenditure (12.7)
Other investing activities (0.2)
Foreign exchange on cash and debt 10.5
Interest and tax (17.0)
Proceeds from previous year disposals of subsidiaries 1.5
New leases (IFRS 16) (11.5)
Shares issued 20.2
Other non-cash movements (1.9)
Net debt at 30 September 2022 (73.7)
Cash flow
With improved trading in all business areas, we saw strong cash generated from
operations of £30.3m (2021: £22m). This also drove higher working capital
levels and taxes, leading to net cash flows generated from operating
activities of £10.8m (2021: £5.8m). Capital expenditure, both intangible and
tangible, showed a significant decrease of £10.0m to £12.7m (2021: £22.7m)
as we worked to moderate our capex and finished off the investment in some of
the growth initiatives, primarily the incubation house in Iceland.
Working capital
Working capital has grown in the period driven by a number of factors. As the
dollar strengthened, we can see the impact on the balance sheet as noted above
in the other comprehensive income section and this increased the working
capital balances at 30 September 2022, but working capital did grow during
FY2022.
We noted earlier the increase in biological assets within the genetics areas.
Other Inventories grew in Nutrition as we had more GSL Artemia in inventory
than previous years to ensure it was available in all locations.
In Health, we had transferred the CleanTreat® equipment into Inventory
resulting in Health inventory increasing by £3.4m.
Trade Debtors and creditors, of course, increased as a result of increased
sales but trade debtors only increased slightly as a % of sales from 19% to
20% in the year. Similarly, trade payables were only slightly higher than last
year.
A significant amount of cash is tied up with the working capital of the group
and focus continued to be on releasing that investment in the years to come.
Refinancing and borrowing facilities
The Group had a NOK 850m senior secured floating rate listed bond which was
due to mature in June 2023 with a coupon of 5.25% above three months Norwegian
Interbank Offered Rate ("NIBOR"). The Group also has a USD 15m revolving
credit facility ("RCF") which was due to mature in December 2022 and had £4m
drawn at 30 September 2022. The interest rate on the facility is between 3%
and 3.5% above LIBOR depending on leverage.
The Company successfully completed a new senior unsecured green bond issue of
NOK 750 million, with an expected maturity date of 27 September 2025. The bond
has a coupon of three months NIBOR* + 6.5% p.a. with quarterly interest
payments.
There are other borrowing facilities held within Benchmark Genetics Salten AS
which were put in place to fund the building of the Salten salmon eggs
facility totalling NOK 227.5m (£18.8m) (2021: NOK 246m (£20.9m)), which are
ringfenced without recourse to the other parts of the Group. Interest on these
other debt facilities ranges between 2.65% and 5% above Norwegian base rates.
In addition, a working capital facility of NOK 20.0m (renewal annual in March)
and an overdraft of NOK 17.5m (maturity December 2022) were in place for use
solely by Benchmark Genetics Salten AS. These facilities are undrawn (2021:
undrawn).
Subsequent Events
Subsequent to the year end, on 21 November 2022, the company successfully
refinanced the RCF facility with a new facility of £20m. The interest rate on
the new RCF was between 2.5% and 3.25% with a maturity of June 2025. In
addition, the term loan facility outstanding balance and the overdraft
facility provided by Nordea were refinanced into one facility on 1 November
2022 totalling NOK179.5m with a maturity date of January 2028. The margin on
the new facility is 2.5%.
Cash and total debt
Net debt £m
2022 2021
Cash 36.4 39.5
NOK 750m bond (2021: NOK 850m) (61.1) (75.5)
Other borrowings (22.8) (20.9)
Lease liabilities (26.2) (24.0)
Net debt (73.7) (80.9)
The RCF facility combined with the year-end cash balance of £36.4m (2021:
£39.5m) means the Group had total liquidity of £45.8m (2021: £50.6m). This,
while utilising tight cost and cash control, is expected by the Directors to
provide the Group with sufficient liquidity to fund the investment and working
capital to crystalise the growth opportunities which are part of the strategic
priorities of the Group and provide adequate headroom.
Equity raise
In November 2021, £20m net proceeds were raised through a placing to provide
the Company with additional headroom to maintain this momentum and to continue
to fund its ongoing growth initiatives.
Oslo listing
During FY2021, the Board commenced a review of our capital structure in the
context of the approaching maturity of the main facilities as noted above and
with regard to funding in the short term for investment opportunities to
accelerate business area growth. As a result the company continues to progress
towards a listing on Euronext Growth Oslo by the end of calendar year 2022. As
previously announced the Company intends to uplist to the Oslo Børs, the
leading seafood and aquaculture market globally, in H1 of calendar year 2023.
The timing of both the listing on Euronext Growth Oslo and intended uplist to
the Oslo Børs is subject to market conditions.
Covenants
Banking covenants for the NOK bond and RCF exist in relation to liquidity and
an 'equity ratio'. Liquidity, defined as 'freely available and unrestricted
cash and cash equivalents, including any undrawn amounts under the RCF', must
always exceed the minimum liquidity value, set at £10m. Available liquidity
at 30 September 2022 is £45.8m (2021: £50.6m). The equity ratio, defined as
'the ratio of Book Equity to Total Assets' must always exceed 40%. The equity
ratio at 30 September 2022 was 61% (2021: 58%). In addition, an equity to
asset ratio covenant exists for the Benchmark Genetics Salten AS debt with a
target threshold of 40%, this equity to asset ratio was 51.3% at 30 September
2022 (2021: 46.2%).
Going concern
As at 30 September 2022 the Group had net assets of £323.3m (2021: £279.6m),
including cash of £36.4m (2021: £39.5m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £30.5m (2021: £11.6m).
As at 30 September 2022 the Company had net assets of £346.6m (2021:
£336.2m), including cash of £3.2m (2021: £9.0m) as set out on the Company
Balance Sheet. The Company made a loss for the year of £16.5m (2021: £3.9m).
As noted in the Strategic Report, we have seen a year of strong performance
following an extended period impacted by COVID-19, with improvements
throughout the year in all of our three business areas. The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.
The year ended with the successful refinancing of its NOK 850 million bond
which was due to mature in June 2023 with the issue of a NOK 750 million
unsecured green bond maturing in 2025. This was achieved against a backdrop of
challenging macroeconomic and market conditions and places the Group in a much
stronger position in light of the ongoing market environment. Additionally,
following the year end, the USD15m RCF was refinanced by a new £20m RCF on 21
November 2022 with a June 2025 maturity. Furthermore, our NOK 216m loan
facility (which had NOK 165.6m outstanding at the year end) which was set to
mature in October 2023 was combined with our NOK 17.5m overdraft facility into
a new loan facility of NOK 179.5m on 1 November 2022, with a new maturity date
in a further 5 years no later than 15 January 2028. Following all of these
refinancing transactions, the Directors are satisfied there are sufficient
facilities in place during the assessment period.
The global economic environment has recently experienced turbulence largely as
a result of the conflict in Eastern Europe with supply issues in a number of
industries impacted and inflation at high levels. Against this backdrop, the
Group shows resilience against these pressures in its forecasts, with
financial instruments in place to fix interest rates and with opportunities
available to mitigate globally high inflation rates, such that even under all
of the above scenario analysis, the Group has sufficient liquidity and
resources throughout the period under review whilst still maintaining adequate
headroom against the borrowing covenants. The Directors therefore remain
confident that the Group has adequate resources to continue to meet its
liabilities as and when they fall due within the period of 12 months from the
date of approval of these financial statements. Based on their assessment, the
Directors believe it remains appropriate to prepare the financial statements
on a going concern basis.
Consolidated Income Statement
for the year ended 30 September 2022
Notes 2022 2021
£000 £000
Revenue 158,277 125,062
Cost of sales (75,149) (59,477)
Gross profit 83,128 65,585
Research and development costs (6,691) (7,010)
Other operating costs (44,661) (38,221)
Share of loss of equity-accounted investees, net of tax (595) (905)
Adjusted EBITDA² 31,181 19,449
Exceptional - restructuring/acquisition-related items 4 16 (184)
EBITDA¹ 31,197 19,265
Depreciation and impairment (19,897) (8,359)
Amortisation and impairment (19,161) (16,283)
Operating loss (7,861) (5,377)
Finance cost 3 (20,057) (7,987)
Finance income 3 4,741 4,185
Loss before taxation (23,177) (9,179)
Tax on loss (7,274) (2,397)
Loss for the year (30,451) (11,576)
(Loss)/profit for the year attributable to:
- Owners of the parent (32,087) (12,891)
- Non-controlling interest 1,636 1,315
(30,451) (11,576)
Earnings per share
Basic loss per share (pence) 5 (4.60) (1.93)
Diluted loss per share (pence) 5 (4.60) (1.93)
1 EBITDA - earnings before interest, tax, depreciation,
amortisation and impairment.
2 Adjusted EBITDA - EBITDA before exceptional and
acquisition-related items.
Consolidated Statement of Comprehensive Income
for the year ended 30 September 2022
2022 2021
£000 £000
Loss for the year (30,451) (11,576)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences 47,606 (9,929)
Cash flow hedges - changes in fair value 2,627 3,054
Cash flow hedges - reclassified to profit or loss 2,546 709
Total comprehensive income for the year 22,328 (17,742)
Total comprehensive income for the year attributable to:
- Owners of the parent 20,326 (19,329)
- Non-controlling interest 2,002 1,587
22,328 (17,742)
Consolidated Balance Sheet
as at 30 September 2022
Notes 2022 2021
£000 £000
Assets
Property, plant and equipment 6 81,900 78,780
Right-of-use assets 7 27,034 25,531
Intangible assets 8 245,264 229,040
Equity-accounted investees 3,113 3,354
Other investments 15 15
Biological and agricultural assets 10 20,878 21,244
Non-current assets 378,204 357,964
Inventories 29,813 20,947
Biological and agricultural assets 10 25,780 17,121
Trade and other receivables 11 56,377 46,498
Cash and cash equivalents 36,399 39,460
Current assets 148,369 124,026
Total assets 526,573 481,990
Liabilities
Trade and other payables 12 (44,324) (46,668)
Loans and borrowings 13 (17,091) (10,654)
Corporation tax liability (10,211) (5,634)
Provisions (1,631) (563)
Current liabilities (73,257) (63,519)
Loans and borrowings 13 (93,045) (109,737)
Other payables 12 (8,996) (911)
Deferred tax (27,990) (28,224)
Non-current liabilities (130,031) (138,872)
Total liabilities (203,288) (202,391)
Net assets 323,285 279,599
Issued capital and reserves attributable to owners of the parent
Share capital 704 670
Additional paid-in capital 420,824 400,682
Capital redemption reserve 5 5
Retained earnings (185,136) (154,231)
Hedging reserve (703) (5,876)
Foreign exchange reserve 77,705 30,465
Equity attributable to owners of the parent 313,399 271,715
Non-controlling interest 9,886 7,884
Total equity and reserves 323,285 279,599
The financial statements were approved and authorised for issue by the Board
of Directors on 30 November 2022 and were signed on its behalf by:
Septima Maguire
Chief Financial Officer
Company number: 04115910
Consolidated Statement of Changes in Equity
for the year ended 30 September 2022
Share Additional paid-in share capital* Other reserves Hedging reserve Retained earnings Total attributable to equity holders of parent Non-controlling interest Total
capital equity
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2020 668 399,601 40,683 (9,651) (142,170) 289,131 6,309 295,440
Comprehensive income for the year
(Loss)/profit for the year - - - - (12,891) (12,891) 1,315 (11,576)
Other comprehensive income - - (10,213) 3,775 - (6,438) 272 (6,166)
Total comprehensive income for the year - - (10,213) 3,775 (12,891) (19,329) 1,587 (17,742)
Contributions by and distributions to owners
Share issue 2 1,081 - - - 1,083 - 1,083
Share-based payment - - - - 830 830 - 830
Total contributions by and distributions to owners 2 1,081 - - 830 1,913 - 1,913
Changes in ownership
Acquisition of NCI - - - - - - (12) (12)
Total changes in ownership interests - - - - - - (12) (12)
Total transactions with owners of the Company 2 1,081 - - 830 1,913 (12) 1,901
As at 30 September 2021 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income for the year
(Loss)/profit for the year - - - - (32,087) (32,087) 1,636 (30,451)
Other comprehensive income - - 47,240 5,173 - 52,413 366 52,779
Total comprehensive income for the year - - 47,240 5,173 (32,087) 20,326 2,002 22,328
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through entity - (562) - - - (562) - (562)
Share-based payment - - - - 1,182 1,182 - 1,182
Total contributions by and distributions to owners 34 20,142 - - 1,182 21,358 - 21,358
Changes in ownership
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company 34 20,142 - - 1,182 21,358 - 21,358
As at 30 September 2022 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Consolidated Statement of Cash Flows
for the year ended 30 September 2022
Notes 2022 2021
£000 £000
Cash flows from operating activities
Loss for the year (30,451) (11,576)
Adjustments for:
Depreciation and impairment of property, plant and equipment 8,602 5,017
Depreciation and impairment of right-of-use assets 11,295 3,342
Amortisation and impairment of intangible fixed assets 19,161 16,283
(Profit)/loss on sale of property, plant and equipment (43) 46
Finance income 3 (319) (1,442)
Finance costs 3 18,437 7,987
Increase in fair value of contingent consideration receivable (1,203) -
Share of loss of equity-accounted investees, net of tax 595 905
Foreign exchange losses/(gains) (3,985) (1,800)
Share-based payment expense 1,182 830
Other adjustments for non-cash items (276) -
Tax expense 7,274 2,397
Increase in trade and other receivables (8,511) (8,178)
Increase in inventories (5,406) (3,554)
Increase in biological and agricultural assets (6,099) (5,427)
Increase in trade and other payables 6,946 5,547
Increase in provisions 1,058 -
18,257 10,377
Income taxes paid (7,447) (4,587)
Net cash flows generated from operating activities 10,810 5,790
Investing activities
Purchases of investments (378) (578)
Receipts from disposal of investments 1,544 9
Purchases of property, plant and equipment (10,808) (17,683)
Purchases of intangibles (205) (225)
Capitalised research and development costs (1,708) (4,813)
Proceeds from sale of fixed assets 220 112
Interest received 119 88
Net cash flows used in investing activities (11,216) (23,090)
Financing activities
Proceeds of share issues 20,737 750
Share-issue costs recognised through equity (562) -
Acquisition of NCI - (12)
Proceeds from bank or other borrowings (net of borrowing fees) 67,939 -
Repayment of bank or other borrowings (74,874) (3,106)
Interest and finance charges paid (9,629) (7,699)
Repayments of lease liabilities (10,533) (4,602)
Net cash flows used in from financing activities (6,922) (14,669)
Net decrease in cash and cash equivalents (7,328) (31,969)
Cash and cash equivalents at beginning of year 39,460 71,605
Effect of movements in exchange rate 4,267 (176)
Cash and cash equivalents at end of year 36,399 39,460
The accompanying notes form part of the financial statements
1. Basis of preparation
These audited results have been prepared on the basis of the accounting
policies which are to be set out in Benchmark Holdings Plc's annual report and
financial statements for the year ended 30 September 2022. Those policies have
been consistently applied to all the years presented unless otherwise stated.
These Group and parent company financial statements were prepared and approved
by the Directors in accordance with UK- adopted International Accounting
Standards in conformity with the requirements of the Companies Act 2006 as it
applies to companies reporting under those standards ("Adopted IFRS"). While
the financial information included in this preliminary statement has been
prepared on the basis of the requirements of IFRSs in issue, this statement
does not itself contain sufficient information to comply with IFRS.
The financial information set out above does not constitute the company's
statutory accounts for the years ended 30 September 2022 or 2021 but is
derived from those accounts. Statutory accounts for 2021 have been delivered
to the registrar of companies, and those for 2022 will be delivered in due
course. The auditor has reported on those accounts. The auditor's report for
2022 was (i) unqualified and (ii) did not contain a statement under section
498(2) or (3) of the Companies Act 2006. Their report for the accounts of 2021
was (i) unqualified, (ii) contained a material uncertainty in respect of
going concern to which the auditor drew attention by way of emphasis without
modifying their report and (iii) did not contain a statement under section
498(2) or (3) of the Companies Act 2006.
The financial statements are prepared on the historical cost basis except that
the following assets and liabilities are stated at their fair value: certain
financial assets and financial liabilities (including contingent consideration
receivable and derivatives) and biological assets measured at fair value.
Non-current assets and disposal groups held for sale are stated at the lower
of previous carrying amount and fair value less costs to sell.
Going concern
As at 30 September 2022 the Group had net assets of £323.3m (2021: £279.6m),
including cash of £36.4m (2021: £39.5m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £30.5m (2021: £11.6m).
As at 30 September 2022 the Company had net assets of £346.6m (2021:
£336.2m), including cash of £3.2m (2021: £9.0m) as set out on the Company
Balance Sheet. The Company made a loss for the year of £16.5m (2021: £3.9m).
As noted in the Strategic Report, we have seen a year of strong performance
following an extended period impacted by COVID-19, with improvements
throughout the year in all of our three business areas. The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan(®)Vet and CleanTreat(®)
offering. Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan(®) Vet and CleanTreat(®) through delayed
roll-out of the revised operating model for the service, together with
reductions in expected biomass treated and reduced treatment prices. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.
The year ended with the successful refinancing of its NOK 850 million bond
which was due to mature in June 2023 with the issue of a NOK 750 million
unsecured green bond maturing in 2025. This was achieved against a backdrop of
challenging macroeconomic and market conditions and places the Group in a much
stronger position in light of the ongoing market environment. Additionally,
following the year end, the USD15m RCF was refinanced with the agreement of a
new GBP20m RCF on 21 November 2022 with a maturity of June 2025. Furthermore,
our NOK 216m loan facility (which had NOK 165.6m outstanding at the year end)
which was set to mature in October 2023 was combined with our NOK 17.5m
overdraft facility into a new loan facility of NOK 179.5m on 1 November 2022,
with a new maturity date in a further 5 years no later than 15 January 2028.
Following all of these refinancing transactions, the Directors are satisfied
there are sufficient facilities in place during the assessment period.
The global economic environment has recently experienced turbulence largely as
a result of the conflict in Eastern Europe with supply issues in a number of
industries impacted and inflation at high levels. Against this backdrop, the
Group shows resilience against these pressures in its forecasts, with
financial instruments in place to fix interest rates and with opportunities
available to mitigate globally high inflation rates, such that even under all
of the above scenario analysis, the Group has sufficient liquidity and
resources throughout the period under review whilst still maintaining adequate
headroom against the borrowing covenants.
The Directors therefore remain confident that the Group has adequate resources
to continue to meet its liabilities as and when they fall due within the
period of 12 months from the date of approval of these financial statements.
Based on their assessment, the Directors believe it remains appropriate to
prepare the financial statements on a going concern basis.
2. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
- Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
- Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
- Health - following the divestment programme completed in the
previous year the segment now focuses on providing health products to the
global aquaculture market.
In order to reconcile the segmental analysis to the Consolidated Income
Statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy was
applied consistently throughout the current and prior period.
Inter- segment
Advanced Nutrition sales
Year ended 30 September 2022 Genetics £000 Health Corporate £000 Total
£000 £000 £000 £000
Revenue 58,008 80,286 20,135 5,120 (5,272) 158,277
Cost of sales (25,971) (37,733) (11,544) 4 95 (75,149)
Gross profit/ (loss) 32,037 42,553 8,591 5,124 (5,177) 83,128
Research and development costs (4,329) (1,990) (372) - - (6,691)
Operating costs (11,133) (21,546) (8,111) (9,048) 5,177 (44,661)
Share of profit of equity-accounted investees, net of tax (595) - - - - (595)
Adjusted EBITDA 15,980 19,017 108 (3,924) - 31,181
Exceptional - restructuring/acquisition related items - (220) 18 218 - 16
EBITDA 15,980 18,797 126 (3,706) - 31,197
Depreciation and impairment (5,322) (2,236) (12,251) (88) - (19,897)
Amortisation and impairment (1,695) (15,000) (2,463) (3) - (19,161)
Operating profit/(loss) 8,963 1,561 (14,588) (3,797) - (7,861)
Finance cost (20,057)
Finance income 4,741
Loss before tax (23,177)
Year ended 30 September 2021 Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
£000 £000 £000 £000 £000 £000
Revenue 46,797 70,530 7,832 4,820 (4,917) 125,062
Cost of sales (20,866) (34,562) (4,118) 2 67 (59,477)
Gross profit/(loss) 25,931 35,968 3,714 4,822 (4,850) 65,585
Research and development costs (4,865) (1,948) (197) - - (7,010)
Other operating costs (8,933) (19,918) (6,202) (8,018) 4,850 (38,221)
Share of loss of equity-accounted investees, net of tax (605) (300) - - - (905)
Adjusted EBITDA 11,528 13,802 (2,685) (3,196) - 19,449
Exceptional - restructuring/acquisition-related items 850 (356) (515) (163) - (184)
EBITDA 12,378 13,446 (3,200) (3,359) - 19,265
Depreciation and impairment (4,166) (2,154) (1,871) (168) - (8,359)
Amortisation and impairment (1,338) (13,896) (1,047) (2) - (16,283)
Operating profit/(loss) 6,874 (2,604) (6,118) (3,529) - (5,377)
Finance cost (7,987)
Finance income 4,185
Loss before tax (9,179)
Non-current assets by location of assets
2022 2021
£000 £000
Belgium 173,135 156,998
Norway 83,752 86,545
UK 42,373 44,629
Iceland 39,448 35,062
Rest of Europe 953 1,062
Rest of world 38,543 33,668
378,204 357,964
3. Net finance costs
2022 2021
£000 £000
Interest received on bank deposits 319 88
Foreign exchange gains on financing activities 4,422 786
Foreign exchange gains on operating activities - 1,957
Cash flow hedges - reclassified from OCI - (709)
Cash flow hedges - ineffective portion of changes in fair value - 2,063
Finance income 4,741 4,185
Finance leases (interest portion) (1,744) (1,076)
Cash flow hedges - reclassified from OCI (2,546) -
Cash flow hedges - ineffective portion of changes in fair value (4,475) -
Foreign exchange losses on operating activities (1,620) -
Interest expense on financial liabilities measured at amortised cost (9,672) (6,911)
Finance costs (20,057) (7,987)
Net finance costs recognised in profit or loss (15,316) (3,802)
4. Exceptional items - restructuring/acquisition-related items
Items that are material because of their nature, non-recurring or whose
significance is sufficient to warrant separate disclosure and identification
within the consolidated financial statements are referred to as exceptional
items. The separate reporting of exceptional items helps to provide an
understanding of the Group's underlying performance.
2022 2021
£000 £000
Acquisition-related items - (850)
Exceptional restructuring costs 1,229 480
Cost in relation to disposals (1,245) 554
Total exceptional items (16) 184
Acquisition-related items are costs incurred in investigating and acquiring
new businesses. In 2021 contingent consideration of
£850,000 was released in relation to the purchase of Benchmark Genetics (USA)
Inc.
Exceptional costs include: £843,000 (2021: £nil) of legal and professional
costs in relation to preparing for listing the Group on the Oslo stock
exchange, and £276,000 (2021: £480,000) relating to restructuring costs.
Costs in relation to disposals includes a credit of £1,203,000 (2021: £nil)
in relation to additional contingent consideration received and receivable
from disposals in previous years (£294,000 relating to the disposal of
Aquaculture UK on 7 February 2020, and £909,000 relating to the disposal of
Improve International Limited and its subsidiaries on 23 June 2020) together
with legal fees, lease costs and disposal items (net of proceeds received)
totalling £42,000 relating to additional costs and disposals proceeds
relating to disposals that occurred in 2020.
5. Loss per share
Basic loss per share is calculated by dividing the profit or loss attributable
to ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
2022 2021
Loss attributable to equity holders of the parent (£000) (32,087) (12,891)
Weighted average number of shares in issue (thousands) 698,233 669,459
Basic loss per share (pence) (4.60) (1.93)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value based on the monetary value of the
subscription rights attached to outstanding share options and warrants.
A total of 6,240,304 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (2021:
4,615,712) as they are anti-dilutive and reduce the loss per share. However,
these potential ordinary shares could dilute earnings per share in the future.
6. Property, plant and equipment
Group
Freehold Land and Buildings Assets in the course of construction Long-Term Leasehold Property Plant and Machinery Office Equipment and Fixtures Total
£000 £000 Improvements £000 £000 £000
£000
Cost
Balance at 1 October 2020 57,856 1,213 5,967 25,149 2,596 92,781
Additions 4,461 4,118 841 7,608 955 17,983
Reclassification (2,075) (371) 38 2,414 (6) -
Increase/(decrease) through transfers from assets in the course of
construction
3,080 (3,080) - - - -
Exchange differences (5) (73) (22) (1,107) (206) (1,413)
Disposals (290) - (403) (1,171) (588) (2,452)
Balance at 30 September 2021 63,027 1,807 6,421 32,893 2,751 106,899
Balance at 1 October 2021 63,027 1,807 6,421 32,893 2,751 106,899
Additions 4,025 1,616 283 4,546 338 10,808
Re-classification to inventory - - - (1,514) - (1,514)
Increase/(decrease) through transfers from assets in the course of 251 (1,275) - 995 29 -
construction
Exchange differences 1,924 116 432 2,377 146 4,995
Disposals (224) - - (131) (126) (481)
Balance at 30 September 2022 69,003 2,264 7,136 39,166 3,138 120,707
Accumulated depreciation
Balance at 1 October 2020 6,481 - 4,984 14,669 1,046 27,180
Depreciation charge for the year 2,120 - 192 2,379 486 5,177
Reversal of impairment in the year - - - (160) - (160)
Exchange differences (541) - (63) (986) (196) (1,786)
Disposals (231) - (390) (1,096) (575) (2,292)
Balance at 30 September 2021 7,829 - 4,723 14,806 761 28,119
Balance at 1 October 2022 7,829 - 4,723 14,806 761 28,119
Depreciation charge for the year 2,387 - 197 5,411 607 8,602
Exchange differences 792 - 256 1,200 141 2,389
Disposals (84) - - (102) (117) (303)
Balance at 30 September 2022 10,924 - 5,176 21,315 1,392 38,807
Net book value
At 30 September 2022 58,079 2,264 1,960 17,851 1,746 81,900
At 30 September 2021 55,198 1,807 1,698 18,087 1,990 78,780
At 1 October 2020 51,375 1,213 983 10,480 1,550 65.601
7. Leases
Group
Right-of-use assets 2022 2021
£000 £000
Leasehold property 9,389 9,859
Plant and machinery 17,582 15,541
Office equipment and fixtures 63 131
27,034 25,531
Lease liabilities 2022 2021
£000 £000
Current 11,522 9,042
Non-current 14,765 14,945
26,287 23,987
Depreciation charge of right-of-use assets 2021 2020
£000 £000
Leasehold property 1,383 1,450
Plant and machinery 9,176 1,718
Office equipment and fixtures 72 74
10,631 3,242
Additional information 2021 2020
£000 £000
Additions to right-of-use assets 497 18,721
Modifications to right-of-use assets 10,884 -
Impairment of leasehold property right-of-use asset 664 100
Interest expense 1,744 1,076
Expense relating to short-term leases 152 371
Expense relating to leases of low-value leases 151 58
Total cash outflow for leases 10,533 6,107
Benchmark Animal Health Limited modified the existing leases for two PSV
vessels, the FS Aquarius and the FS Pegasus to extend the lease term only.
These two assets constitute £15,741,399 of the net book value and
£15,358,543 of the lease liability at the year end.
8. Intangible assets
Group
Websites Goodwill Patents and Trademarks Intellectual Property Customer Lists Contracts Licences Genetics Development costs Total
£000 £000 £000 £000 £000 £000 £000 £000 £000 £000
Cost or valuation
Balance at 1 October 2020 201 144,346 270 138,718 5,497 6,561 35,559 22,182 23,057 376,391
Additions - 115 - 68 - - - 42 - - 225
externally acquired
Additions - internally developed - - - - - - - - 4,813 4,813
Exchange differences 3 (4,291) - (5,517) (226) 41 (1,122) 454 (291) (10,949)
Balance at 319 140,055 338 133,201 5,271 6,602 34,479 22,636 27,579 370,480
30 September 2021
Balance at 1 October 2021 319 140,055 338 133,201 5,271 6,602 34,479 22,636 27,579 370,480
Additions - externally acquired 94 - 111 - - - - - - 205
Additions - internally developed - - - - - - - - 1,708 1,708
Exchange differences 34 24,619 3 27,206 1,107 (27) 5,841 599 1,935 61,317
Balance at 447 164,674 452 160,407 6,378 6,575 40,320 23,235 31,222 433,710
30 September 2022
Accumulated amortisation and impairment
Balance at 1 October 2020 26 43,101 81 63,163 1,005 6,114 11,376 3,431 1,091 129,388
Amortisation charge for the period 41 - 53 12,707 199 66 1,909 622 299 15,896
Impairment - - - - - - - - 387 387
Exchange differences - (1,743) (1) (2,329) (38) 30 (208) 58 - (4,231)
Balance at 30 September 2021 67 41,358 133 73,541 1,166 6,210 13,077 4,111 1,777 141,440
Balance at 1 October 2021 67 41,358 133 73,541 1,166 6,210 13,077 4,111 1,777 141,440
Amortisation charge for the period 67 - 70 13,574 215 102 2027 636 2,165 18,856
Impairment - - - 305 - - - - - 305
Exchange differences 9 8,592 3 16,966 275 (19) 1,839 139 41 27,845
Balance at 30 September 2022 143 49,950 206 104,386 1,656 6,293 16,943 4,886 3,983 188,446
Net book value
At 30 September 2022 304 114,724 246 56,021 4,722 282 23,377 18,349 27,239 245,264
At 30 September 2021 252 98,697 205 59,660 4,105 392 21,402 18,525 25,802 229,040
At 1 October 2020 175 101,245 189 75,555 4,492 447 24,183 18,751 21,966 247,003
The table below provides further detail of intangibles and their remaining
amortisation period.
Description Category Net book value Net book value Remaining
2022 2021 life
2022
Acquisition of INVE in 2015
Goodwill Goodwill 87,585 72,385 -
Harvesting rights Licences 22,449 19,599 13
Product technology Intellectual property 446 1,843 0
Product rights Intellectual property 39,390 42,571 3
Brand names Intellectual property 12,976 11,533 13
In-process R&D Intellectual property 847 915 3
Customer relationships Customer lists 4,723 4,105 19
Total relating to acquisition of INVE 168,416 152,951
Acquisition of Salmobreed AS (Now part of Benchmark Genetics Norway AS) in
2014
Goodwill Goodwill 6,523 6,703 -
Genetic material and breeding nuclei Genetics 9,911 10,500 32
Total relating to acquisition of Salmobreed AS 16,434 17,203
Acquisition of Stofnfiskur (now Benchmark Genetics Iceland) in 2014
Goodwill Goodwill 12,467 11,394 -
Genetic material and breeding nuclei Genetics 8,147 7,677 32
Total relating to acquisition of Stofnfiskur 20,614 19,071
Acquisition of Akvaforsk Genetics Center AS (Now part of Benchmark Genetics
Norway AS) in 2015
Goodwill Goodwill 7,348 7,552 -
Licences Licences 292 662 1
Contracts Contracts 282 392 3
Total relating to acquisition of Akvaforsk Genetics Center AS 7,922 8,606
Capitalised development costs
Ectosan(®)Vet/CleanTreat(®) Development costs 15,840 17,621 9
Live food alternative diets Development costs 4,115 3,318 Not yet ready for use
SPR shrimp Development costs 6,686 4,863 Not yet ready for use
Total capitalised development costs 26,641 25,802
Other purchased material intangible assets Intellectual property 1,497 1,586 17
Total relating to other purchased intangible assets 1,497 1,586
Other individually immaterial goodwill and intangible assets 3,740 3,821
Total net book value at 30 September 245,264 229,040
9. Impairment testing of goodwill and other intangible assets
The Group tests goodwill and other intangibles not yet ready for use annually
for impairment, or more frequently if there are indications that goodwill or
the other intangible assets might be impaired. Goodwill acquired in a business
combination is allocated, at acquisition, to the cash generating units (CGUs)
that are expected to benefit from the business combination. The only
intangible assets not yet ready for use are generally the capitalised
development costs on internally developed products. Following the commercial
launch of the SPR Shrimp product in Genetics, amortisation of these
development costs commenced during the year. The development costs included in
the table below represents only those that are not yet ready for use.
Due to the interdependence of the operations within each of the business areas
and the way in which they are managed, management have determined the CGUs are
the business areas themselves - Health, Genetics and Advanced Nutrition. These
are the smallest groups of assets that independently generate cashflows and
whose cashflows are largely independent of those generated by other assets.
Goodwill and capitalised development costs arise across the Group, and are
allocated specifically against the CGUs as follows:
Genetics Advanced Nutrition Health Total
2022 2022 2022 2022
£000 £000 £000 £000
Benchmark Genetics Norway AS 6,523 - - 6,523
Benchmark Genetics Iceland HF (Previously Stofnfiskur HF) 12,467 - - 12,467
Akvaforsk Genetic Center* 8,150 - - 8,150
INVE Aquaculture Group - 87,585 - 87,585
Goodwill 27,140 87,585 - 114,725
Other intangibles not yet ready for use - development costs - 4,115 - 4,115
* Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).
Genetics Advanced Nutrition Health Total
2021 2021 2021 2021
£000 £000 £000 £000
Benchmark Genetics Norway AS 6,702 - - 6,702
Benchmark Genetics Iceland HF (Previously Stofnfiskur HF) 11,394 - - 11,394
Akvaforsk Genetic Center* 8,216 - - 8,216
INVE Aquaculture Group - 72,385 - 72,385
Goodwill 26,312 72,385 - 98,697
Other intangibles not yet ready for use - development costs 4,863 3,318 - 8,181
* Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).
The recoverable amounts of the above CGUs have been determined from
value-in-use calculations. These calculations used Board approved cash flow
projections from five-year business plans based on actual operating results
and current forecasts. These forecasts were then extrapolated into perpetuity
taking account of specific terminal growth rates for future cash flows, using
individual business operating margins based on past experience and future
expectations in light of anticipated economic and market conditions. The
pre-tax cash flows that these projections produced were discounted at pre-tax
discount rates based on the Group's beta adjusted cost of capital, further
adjusted to reflect management's assessment of specific risks related to the
markets and other factors pertaining to each CGU. Forecasts also include any
costs in relation to the Group's climate change strategy and climate change
factors have been considered when setting the long-term growth rates.
The values assigned to the key assumptions represent management's assessment
of future trends in the relevant industries and have been based on historical
data from both external and internal sources.
Specific assumptions used are as follows:
Genetics
Amortisation of the development costs relating to the business area's new SPR
Shrimp product commenced in the period.
The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 14.7% (2021: 10.9%). CAGR of revenue of 15% (2021:
14%) is implied by the five-year plan and a long-term growth rate of 2.5%
(2021: 2.5%) has been used to extrapolate the terminal year cashflow into
perpetuity.
Having conducted a sensitivity analysis of key assumptions, no reasonably
possible changes that would result in the elimination
of all headroom were identified.
Advanced Nutrition
The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 15.6% (2021: 10.3%). CAGR of revenue of 10% (2021:
6%) is implied by the five-year plan and a long-term growth rate of 3.5%
(2021: 3.5%) has been used to extrapolate the terminal year cashflow into
perpetuity. Market analysis reports predict long-term growth rates of c5.0%,
and the health benefits of shrimp are still very much in evidence. Management
have used a long-term growth rate of 3.5% to represent both a prudent and
consistent approach for the CGU.
The value in use assessment is sensitive to changes in the key assumptions
used. All other assumptions being unchanged a decrease in the long-term growth
rate to 1.8% or an increase in the pre-tax discount rate to 16.8%, either of
which are considered to be reasonably possible, would reduce the headroom on
the Advanced Animal Nutrition CGU of £21.6m to nil.
Should the discount rate increase further than this, then an impairment of the
goodwill or development costs would be likely.
In the work done during the year in assessing the risks caused by climate
change, there is a risk associated with the water levels in the Great Salt
Lake which is a key source of artemia for the Group. The mitigating actions
noted in that review mean that this is not currently a trigger event causing
our forecasts to be sensitised for this risk. However, should the water levels
fall to a level that could not sustain production of artemia, this might lead
to an impairment. Were this to occur, other mitigating actions available to
the Group including obtaining artemia from other globally available sources
and exploiting our Diets portfolio to reduce the use of artemia in our feed
programmes would be explored. As a result, management believe that no
impairment to the carrying value of the intangible assets is required.
Health
The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 16.4% (2021: 12.6%). An assumed CAGR of revenue of
27% (2021: 70%) in the five-year plan reflects the importance of the
successful commercial ramp- up of the business area's new sea lice treatment
in the forecast period. A long-term growth rate of 0.0% (2021: 0.0%) has been
used to extrapolate the terminal year cashflow into perpetuity. The prudent
assumption in the long-term growth rate is intended to reflect that the
business area's new sea lice treatment is the principal source of cash
generation, and only benefits from patent protection against generic
competitors for a finite period of time.
The valuation of the Health cash generating unit indicates sufficient headroom
such that a reasonably possible change to key assumptions is unlikely to
result in an impairment in related development costs.
While the valuation of the Health cash-generating unit indicates sufficient
headroom such that any reasonably possible change to key assumptions is
unlikely to result in an impairment in related development costs,
commercialisation is at an early stage and in the unlikely event that this is
not successful, impairment could result.
10. Biological assets
Book value of biological assets recognised at fair value
2022 2021
Group £000 £000
Salmon eggs 14,037 9,830
Salmon broodstock 30,501 26,700
Salmon milt 606 365
Lumpfish fingerlings 1,090 1,104
Shrimp 424 366
Total biological assets 30 September 46,658 38,365
Analysed as
Current 25,780 17,121
Non-current 20,878 21,244
Total biological assets 30 September 46,658 38,365
Change in book value of biological assets
2021 2020
£000 £000
Biological assets 1 October 38,365 32,469
Increase from production 48,067 36,872
Reduction due to sales (43,535) (34,768)
Other movements in biological assets 4,532 2,104
Foreign exchange movement before fair value adjustment 1,704 311
Change in fair value through income statement 1,595 3,323
Foreign exchange impact on fair value adjustment 462 158
Biological assets 30 September 46,658 38,365
Assumptions used for determining fair value of biological assets
IAS 41 requires that biological assets are accounted for at the estimated fair
value net of selling and harvesting costs. Fair value is measured in
accordance with IFRS 13 and is categorised into levels in the fair value
hierarchy.
The fair value inputs for salmon eggs are categorised as level 2. The
calculation of the fair value of the salmon eggs is based upon the current
seasonally adjusted selling prices for salmon eggs less transport and
incubation costs and taking account of the market capacity. The valuation also
takes account of the mortality rates of the eggs and expected life as sourced
from internally generated data.
The fair value inputs for salmon broodstock are categorised as level 3. The
broodstock contain generations of genetic improvements and cannot be valued
purely on the market weight of salmon. The Group does not sell its broodstock
commercially so there is no observable input in this respect. Therefore, the
calculation of the estimated fair value of salmon broodstock is primarily
based upon its main harvest output being salmon eggs, which are priced upon
the current seasonally adjusted selling prices for the Group's salmon eggs.
These prices are reduced for harvesting costs, freight costs, incubation costs
and market capacity to arrive at the net value of broodstock. The valuation
also reflects the internally generated data to arrive at the biomass. This
includes the weight of the broodstock, the yield that each kilogram of fish
will produce and mortality rates. The fish take four years to reach maturity,
and the age and biomass of the fish is taken into account in the fair value.
Finally, the valuation takes account of future expected sales volumes.
Change in book value of salmon broodstock
2022 2021
£000 £000
Biological assets 1 October 26,700 21,051
Increase from production 28,720 22,428
Transfer to salmon eggs following harvesting (26,509) (19,602)
Foreign exchange movement before fair value adjustment 1,326 169
Change in fair value through income statement (31) 2,530
Foreign exchange impact on fair value adjustment 295 124
Biological assets 30 September 30,501 26,700
Significant unobservable inputs used in the valuation of salmon broodstock
2022 2021
Number of eggs valued in broodstock (m units) 222 192
Average selling price per egg (GBP) 0.135 0.128
Future costs per egg (GBP) (0.021) (0.015)
The fair value inputs for lumpfish fingerlings and shrimp are categorised as
level 2. The calculation of the fair value of lumpfish fingerlings and shrimp
is valued on current selling prices less transport costs. Internally generated
data is used to incorporate mortality rates and the weight of the biomass.
The fair value inputs for salmon milt are categorised as level 3. Where we
have identified individual salmon carrying particular traits or disease
resistance, semen (milt) can be extracted and deep-frozen using
cryopreservation techniques (the process of freezing biological material at
extreme temperatures in liquid nitrogen). The calculation of the fair value of
milt is based on production and freezing costs and, where appropriate, an
uplift to recognise the additional selling price that can be achieved from
eggs fertilised by premium quality milt.
There is a presumption that fair value can be measured reliably for a
biological asset. However, we sometimes face a situation where alternative
estimates of fair value are determined to be clearly unreliable (for example,
where we establish a new broodstock farm in a new territory). In such a case,
that biological asset shall be measured at its cost less any accumulated
impairment losses. In the year this applied to £1,969,000 of broodstock in
Chile. As at 30 September the gross carrying amount was £4,704,000 (2021:
£4,674,000) and the accumulated impairment losses were £2,735,000 (2021:
£2,507,000).
The valuation models by their nature are based upon uncertain assumptions on
sales prices, market capacity, weight, mortality rates, yields and assessment
of the discounts to reflect the stages of maturity. The Group has a degree of
expertise in these assumptions but these assumptions are subject to change.
Relatively small changes in assumptions would have a significant impact on the
valuation. A 1% increase/decrease in assumed selling price would
increase/decrease the fair value of biological assets by £445,000. A 10%
increase/decrease in the biomass of salmon broodstock and the quantity of
salmon eggs valued would increase/decrease the fair value of those biological
assets by £4,450,000.
The Group is exposed to financial risks arising from changes in the market
value of the salmon eggs, lumpfish fingerlings and shrimp broodstock that it
sells. The Group does not anticipate that prices will decline significantly in
the foreseeable future and, therefore, has not entered into derivative or
other contracts to manage the risk of a decline in the price of its products.
The Group reviews its outlook for salmon eggs, lumpfish fingerlings and shrimp
broodstock prices regularly in considering the need for active financial risk
management.
Risk management strategy related to aquaculture activity
The Group is exposed to the following risks relating to its aquaculture
activities. These risks and management's strategies to mitigate them are
described below:
Regulatory and environmental risks
The nature of certain of the Group's operating activities exposes us to
certain significant risks to the environment, such as incidents associated
with releases of chemicals or hazardous substances when conducting our
operations, which could result in liability, fines, risk to our product
permissions and reputational damage. There is a risk that natural disasters
could lead to damage to infrastructure, loss of resources, products or
containment of hazardous substances. Our business activities could be
disrupted if we do not respond, or are perceived not to respond, in an
appropriate manner to any major crisis or if we are not able to restore or
replace critical operational capacity.
In mitigation we have implemented standards and requirements which govern key
risk management activities such as inspection, maintenance, testing, business
continuity and crisis response.
Biological risks
The Group is exposed to the risk of disease within the Group's own operations
and disease in the market resulting in possible border closures. In
mitigation, the Group:
- Operates the highest levels of biosecurity.
- Holds genetic stock at multiple sites and increasingly sources
from its own land-based salmon breeding facilities.
- Operates containment zones which mitigates the risk of border
closures affecting its ability to import or export.
- Has placed increased focus on insuring its biological stock.
Outputs and quantities held
Total output of aquaculture activity in the year was:
2022 2021
Salmon eggs 291.1m units 242.0m units
Lumpfish fingerlings 2.0m units 2.4m units
Total quantities held at 30 September were:
2022 2021
Salmon eggs 103.9m units 79.9m units
Salmon broodstock 1,737 tonnes 1,577 tonnes
Lumpfish fingerlings 0.7m units 2.6m units
11. Trade and other receivables
Group 2022 2021
£000 £000
Trade receivables 31,218 24,526
Less: provision for impairment of trade receivables (2,748) (2,493)
Trade receivables - net 28,470 22,033
Total financial assets other than cash and cash equivalents measured at 28,470 22,033
amortised cost
Other receivables - contingent consideration 887 1,028
Total financial assets other than cash and cash equivalents classified as 887 1,028
measured at fair value through profit and loss
Prepayments 14,989 11,114
Other receivables 12,031 12,323
Total trade and other receivables 56,377 46,498
Other receivables relate to the following items: VAT recoverable £4,386,000
(2021: £2,650,000), research and development expenditure tax credits and
similar items £154,000 (2021: £472,000), the right to receive an agreed
proportion of a key supplier's harvest* £5,249,000 (2021: £7,302,200),
accrued income of £1,377,000 (2021: £348,000) and other amounts receivable
of £865,000 (2021: £1,551,000).
*A financial liability of £5,249,000 (2021: £7,302,200) is recognised
(within trade payables) for the amount invoiced and remaining outstanding at
the year-end in relation to the Group's contractual obligation to pay for a
specified share of the harvest of a supplier, regardless of delivery and
without recourse to the supplier. As at 30 September, as the Group has not
taken physical delivery of the harvested product and as the Group does not
control the harvested product, an 'other receivable' of £5,249,000 (2021:
£7,302,200) has been recorded in relation to the Group's right to receive the
product in the future.
The financial asset at fair value through profit and loss relates to
contingent consideration outstanding from the disposal of Improve
International Limited in FY20. This relates to deferred cash consideration
dependent on the delivery of certain future revenues in the financial year
ended 30 September 2022 and the fair value is derived from the likely
receivable amount based on current expectations of performance against the
targets.
The fair values of trade and other receivables measured at amortised cost are
not materially different to their carrying values. As at 30 September 2022
trade receivables of £5,943,000 (2021: £3,060,000) were past due but not
impaired. They relate to customers with no default history. The ageing
analysis of these receivables is as follows:
2022 2021
£000 £000
Up to 3 months overdue 5,761 2,703
3 to 6 months overdue 218 211
6 to 12 months overdue (36) 146
5,943 3,060
Movements on the Group provision for impairment of trade receivables are as
follows:
2022 2021
£000 £000
At 1 October 2,493 3,216
Provided during the year 281 54
Unused provisions reversed (180) (637)
Receivables written off during the year as uncollectable - (22)
Foreign exchange movements 154 (118)
At 30 September 2,748 2,493
The movement on the provision for impaired receivables has been included in
the operating costs line in the Consolidated Income Statement.
Other classes of financial assets included within trade and other receivables
do not contain impaired assets.
12. Trade and other payables
Group 2022 2021
£000 £000
Trade payables 22,149 20,690
Other payables 1,127 1,978
Accruals 17,636 15,812
Other payables - tax and social security payments 3,799 2,076
Financial liabilities, excluding loans and borrowings, classified as financial 44,711 40,556
liabilities measured at amortised cost
Financial contracts - hedging instrument 7,991 972
Financial liabilities, excluding loans and borrowings, classified as financial 7,991 972
liabilities at fair value through profit or loss
Financial contracts - hedging instrument 21 5,889
Financial liabilities, excluding loans and borrowings, classified as financial 21 5,889
liabilities at fair value through hedging reserve
Deferred income 597 162
Total trade and other payables 53,320 47,579
Less: non-current: contingent consideration in other payables and financial (8,996) (911)
contracts
Current portion 44,324 46,668
Of the financial contracts £8,387,000 (2021: £6.708,000) relates to a NOKUSD
floating to fixed cross-currency interest rate swap (CCS) and a NOK interest
rate swap (IRS), both of which were entered to fully match the timing and
tenor of the underlying new senior secured floating rate listed bond issue of
NOK 750m.
The floating-to-fixed NOK IRS (notional NOK 300m) is designated a cash flow
hedge where any changes in the fair value of the swap will be taken directly
to equity within the hedging reserve and recycled to profit or loss as the
bond impacts the profit or loss.
The NOKUSD CCS (notional NOK450m) has been separated into two synthetic swaps;
the first is a floating-to-fixed NOKGBP interest rate swap, being a cash flow
hedge of the foreign exchange and interest rate risk on NOK denominated debt.
The fair value of this synthetic swap is posted to the hedging reserve in
equity. The second synthetic swap is a fixed-to-fixed GBPUSD swap designated
as a net investment hedge in the USD net assets in the consolidated accounts
of Benchmark Holdings plc. The fair value of this leg is posted to the foreign
exchange translation reserve in equity.
13. Loans and borrowings
Group
2022 2021
£000 £000
Non-Current
2025 750m NOK Loan notes 61,054 -
2023 850m NOK Loan notes - 75,478
Bank borrowings 17,226 19,314
Lease liabilities 14,765 14,945
93,045 109,737
Current
Bank borrowings 5,569 1,612
Lease liabilities 11,522 9,042
17,091 10,654
Total loans and borrowings 110,136 120,391
At 30 September 2022 the fair value of the unsecured floating rate listed
green bond of NOK 750m was not materially different to the nominal value and
has not been separately disclosed. At 30 September 2021 the fair value of 2023
850m NOK Loan notes was £73,981,000.
On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments, and is to be listed on the Oslo Stock Exchange. The proceeds were
used to repay the NOK 850m floating rate listed bond, originally raised in
June 2019.
A USD 15m Revolving Credit Facility ("RCF") has been provided by DNB Bank ASA
(50%) and HSBC UK Bank PLC (50%). At 30 September 2022 £4,000,000 was drawn
on this facility. The facility was undrawn at 30 September 2021.
Benchmark Genetics Salten AS (formerly SalmoBreed Salten AS) had the following
loans (which are ring-fenced debt without recourse to the remainder of the
Group) at 30 September 2022:
- Term loan with a balance of NOK 165.6m (2021: NOK 180.0m)
provided by Nordea Bank Norge Abp. The loan is a five-year term loan ending
November 2023 at an interest rate of 2.5% above three-month NIBOR.
- NOK 20.0m 12-month working capital facility provided by Nordea
Bank Norge Abp. This was undrawn at 30 September 2022 (2021: undrawn).
- An additional NOK 17.5m overdraft facility was provided by
Nordea Bank Norge Abp during the year with maturity in December 2022. This
facility was undrawn at 30 September 2022.
- Term loan with a balance of NOK 40.1m (2021: NOK 44.7m) provided
by Innovasjon Norge. The loan is a 12-and-a-half-year term loan maturing in
March 2031. The interest rate on this loan at 30 September 2022 was 4.95%. The
interest rate on this loan is variable.
- NOK 21.75m loan provided by Salten Aqua ASA (the minority
shareholder). The loan attracts interest at 2.5% above three-month NIBOR and
is repayable on maturity of the Nordea term loan above.
Subsequent to the year end on 1 November 2022, the Nordea Bank term loan above
was refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms remain the same.
Furthermore on 21 November 2022, the Group refinanced the USD15m RCF with a
secured GBP20m RCF provided by DNB Bank ASA, maturing on 27 June 2025. The
margin on this facility is a minimum of 2.75% and a maximum of 3.25%,
dependent upon the leverage of the Group above the relevant risk free
reference or IBOR rates depending on which currency is drawn.
The lease liabilities are secured on the assets to which they relate.
The currency profile of the Group's loans and borrowings is as follows:
2022 2021
£000 £000
Sterling 16,619 13,912
Norwegian Krone 80,712 97,389
Thai Baht 954 1,258
Euro 272 351
US Dollar 10,888 6,508
Icelandic Krone 545 750
Other 146 223
110,136 120,391
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FR LKLLLLFLFFBQ